GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » Market Cap

HUMA (Humacyte) Market Cap : $527.54 Mil (As of Dec. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Humacyte Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Humacyte's share price for the quarter that ended in Sep. 2024 was $5.44. Humacyte's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 119.84 Mil. Therefore, Humacyte's market cap for the quarter that ended in Sep. 2024 was $651.95 Mil.

Humacyte's quarterly market cap increased from Mar. 2024 ($370.35 Mil) to Jun. 2024 ($572.87 Mil) and increased from Jun. 2024 ($572.87 Mil) to Sep. 2024 ($651.95 Mil).

Humacyte's annual market cap declined from Dec. 2021 ($746.78 Mil) to Dec. 2022 ($217.81 Mil) but then increased from Dec. 2022 ($217.81 Mil) to Dec. 2023 ($294.43 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Humacyte's Enterprise Value for Today is $524.24 Mil.


Humacyte Market Cap Historical Data

The historical data trend for Humacyte's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte Market Cap Chart

Humacyte Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Market Cap
- 746.78 217.81 294.43

Humacyte Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 303.14 294.43 370.35 572.87 651.95

Competitive Comparison of Humacyte's Market Cap

For the Biotechnology subindustry, Humacyte's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humacyte's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's Market Cap distribution charts can be found below:

* The bar in red indicates where Humacyte's Market Cap falls into.



Humacyte Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Humacyte's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=$2.84*103.674
=$294.43

Humacyte's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=$5.44*119.843
=$651.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Humacyte  (NAS:HUMA) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Humacyte Market Cap Related Terms

Thank you for viewing the detailed overview of Humacyte's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Humacyte Business Description

Traded in Other Exchanges
N/A
Address
2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Executives
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Laura E Niklason director, 10 percent owner, officer: President, CEO and Director 35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan director, 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Kathleen Sebelius director C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Dale A. Sander officer: CFO & CCDO 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
Heather Ledbetter Prichard officer: Chief Operating Officer 820 BROWNWICH STREET, WAKE FOREST NC 27587
Max N. Wallace director 210 WEST TRYON STREET, HILLSBOROUGH NC 27278
Gordon M Binder director 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Ayabudge Llc 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
William John Scheessele officer: Chief Commercial Officer 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao officer: Chief Regulatory Officer 12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green director 3185 SCENIC DRIVE, NAPA CA 94558
Diane Seimetz director JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh officer: Chief Medical Officer 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla director EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411

Humacyte Headlines

From GuruFocus